Researchers at Bar-Ilan University and the Galilee Medical Center identified an association between vitamin D deficiency and severity and mortality of COVID-19.
COVID Update: Pill Production Underway and Vaccines in Pregnant Women
Animals, Antivirals, Babies, COVID-19 Vaccinations, CVS Health, Infusion Therapy, JAMA, Long COVID, Massachusetts General Hospital, Merck, Molnupiravir, National Institutes of Health, Paxlovid, Pfizer, Pharmacies, Pills, Pregnancies, R&D, Remdesivir, Retail Pharmacies, SARS-CoV-2 virus, TherapeuticsMerck & Co. and Ridgeback Biotherapeutics announced they have supplied about 3.1 million courses of their antiviral drug against COVID-19, molnupiravir, to the U.S. government. In other news, a study funded by the National Institutes of Health found that vaccination against COVID-19 not only protects pregnant women against the disease but their babies as well.
Paxlovid Deal Details and Assessment of Pandemic Response Begins
Antiparasitics, Antivirals, Biotechnology, BNT162b2 (Pfizer and BioNTech), Boston University, Business, Children, Contracts, Coronavirus Disease (COVID-19) Pandemic, Covid-19 Data, COVID-19 Doses, COVID-19 Mortality, COVID-19 Vaccines, Cuba, Doctors, Inflammation, Ivermectin, Janssen COVID-19 Vaccine (J&J), Johns Hopkins, Nature, Omicron (B.1.1.529) (South Africa), Omicron BA.2, Paxlovid, Pfizer, R&D, RNA Polymerase, T-Cells, U.S. government, University of MichiganAside from vaccines, the advent of several effective COVID-19 antiviral therapies, including Pfizer’s Paxlovid, provides hope for ending the pandemic. Details about the U.S. government’s contract with Pfizer for 10 million doses of Paxlovid are emerging, with some unusual elements.
Gilead Sciences Inc.’s COVID-19 drug remdesivir during 2021 overtook AbbVie Inc.’s 20-year-old arthritis drug Humira as the medicine that U.S. hospitals spent the most on, according to Vizient Inc., a purchasing group used by about half the nation’s hospitals.
About 35% of People Who Received Placebo in Vaccine Trials Report Side Effects and More COVID-19 News
Adverse Events, BNT162b2 (Pfizer and BioNTech), Business, CDC, Clinical Trials, COVID-19 Antibodies, COVID-19 forecasts, COVID-19 Studies, COVID-19 Vaccines, Harvard Medical School, Intensive Care Units (ICUs), JAMA, Janssen COVID-19 Vaccine (J&J), Johnson & Johnson, Long COVID, mRNA-1273/Moderna COVID-19 Vaccine (Moderna), Nature Communications, Omicron (B.1.1.529) (South Africa), Placebo, R&D, Side Effects, The NetherlandsAccording to a recent study conducted by researchers at Harvard Medical School and Beth Israel Deaconess Medical Center, 76 percent of the adverse side effects (such as fatigue or headache) that people experienced after receiving their first COVID-19 vaccination were also reported by participants who received a placebo shot.
The Omicron variant appears to result in less severe COVID-19 than seen during previous periods of high coronavirus transmission including the Delta wave, with shorter hospital stays, less need for intensive care and fewer deaths, according to a new U.S. study.
The U.S. government will make 400 million non-surgical N95 masks from its strategic national stockpile available for free to the public starting next week, a White House official said, marking the Biden administration’s latest effort to help curb the COVID-19 pandemic.
Top U.S. infectious disease expert Anthony Fauci warned on January 5 against complacency about the Omicron variant of the coronavirus, saying the sheer number of cases could strain hospitals despite signs of lower severity.
Zyter published a white paper focused on how evolving applications of IoT technologies are driving future growth and innovation for smart hospitals.
Union leaders representing 50,000 nurses and other U.S. medical staff reached a tentative agreement with Kaiser Permanente on November 13, averting a strike that could have disrupted patient care at hospitals.